Acute Respiratory Distress Syndrome News and Research

RSS

Study links barotrauma to COVID-19 in younger patients

To better understand the possible relationship between severe infection and poor in-hospital outcomes, researchers from the Internal Medicine, and the Pulmonary Critical Care Medicine, Rutgers University, Newark, USA, presented a case series linking barotrauma to COVID-19 in younger patients.

28 May 2021

The potential therapeutic value of CDK6 inhibitors in critical COVID-19

While drug repurposing has been explored in the context of the current coronavirus disease 2019 (COVID-19) pandemic, the success of this strategy has been limited so far. A new study, released as a preprint on the medRxiv* server, describes a new method of identifying a promising hit among drugs already in use.

24 May 2021

Which biomarkers can help predict adverse outcomes in COVID-19?

A team of researchers has conducted a systematic review to identify laboratory factors that can predict the risk of severe and critical COVID-19 as well as associated mortality rates. The team – from institutions in India and the USA – recently published their findings in the Journal of Clinical Medicine Research.

24 May 2021

Research suggests Garcinia kola extract might suppress severe COVID-19 cytokine storms

Researchers in the UK and Nigeria have conducted a study showing that Garcinia kola seed extract and garcinoic acid may provide therapeutic benefits in the late stage of severe coronavirus disease 2019 (COVID-19) and other coronavirus infections.

24 May 2021

Decreasing activity of ZMPSTE24 protease with age and comorbidities may make elderly COVID-19 patients vulnerable

Studies have shown that circulating levels of PAI-1, the coagulation cascade activator, are considerably higher in COVID-19 patients with severe respiratory illness compared to patients with bacterial-sepsis and acute respiratory distress syndrome (ARDS). Hence the increase in PAI-1 levels is recognized as an early marker of endothelial dysfunction in COVID-19 patients.

23 May 2021

Antibody to SARS-CoV-2 inhibits complement hyperactivation

Although several monoclonal antibodies against the SARS-CoV-2 spike protein have been developed and clinically tested, little is known about antibodies to the nucleocapsid protein. In a paper published recently in the journal Nature Communications, researchers report a human monoclonal antibody that targets the nucleocapsid protein.

17 May 2021

Researchers use ultrasound to reduce COVID-19-related inflammation

Researchers at University of California San Diego School of Medicine have begun a pilot clinical trial to test the efficacy of using ultrasound to stimulate the spleen and reduce COVID-19-related inflammation, decreasing the length of hospital stays.

13 May 2021

Comprehensive blood atlas of COVID-19 identifies hallmarks of disease severity

Researchers in the UK have presented a multi-omics integrated blood atlas that delineates the host immune response in patients with coronavirus disease 2019 (COVID-19) of varying severity, providing a unique reference resource for the interpretation of datasets generated from interventional trials.

13 May 2021

AI methods predict COVID-19 patient outcomes using routine clinical data from ICUs

The investigators used machine learning to predict which patients might get worse and not respond positively to being turned onto their front in intensive care units (ICUs) - a technique known as proning that is commonly used in this setting to improve oxygenation of the lungs.

11 May 2021

Severe COVID-19 linked to genetic clotting predisposition

Thus, the need to stratify the risk of severe or critical disease in patients presenting with SARS-CoV-2 infection remains a crying necessity. A new preprint research paper posted to the medRxiv server discusses the relationship between severe disease and pre-existing susceptibility to clots and other diseases of the cardiovascular system.

11 May 2021

Is COVID-19 a new disease?

In a review recently published in The Lancet Respiratory Medicine journal by Osuchowski et al. (May 6th, 2021) the currently known pathophysiology of COVID-19 is laid out to describe the mechanistic features that make COVID-19 distinct from many conditions previously thought to be similar.

9 May 2021

Researchers identify anti-inflammatory prodrug Minnelide with potential against SARS-CoV-2

Using a transgenic mouse model of COVID-19, they have observed that treatment with Minnelide reduces viral load and inflammation in the lungs and improves survival. The study is currently available on the bioRxiv* preprint server.

9 May 2021

Are infants at greater risk of COVID-19 than children?

The widely circulating SARS-CoV-2 has caused the devastating COVID-19 pandemic. The impact of this infection varies significantly with age, sparing young children for the most part, though not completely. However, a new study, released as a preprint on the medRxiv* server, shows that infants are not as resistant to the virus as children are. The researchers trace this to the expression of ACE2 to varying extents in different groups.

7 May 2021

Could stem cells improve the outcome of ARDS in severe COVID-19?

A recent study, published in Stem Cells Translational Medicine, explores the safety and efficacy of stem cells, which have been touted as the panacea for a wide range of illnesses, ranging from chronic degenerative conditions to cancer.

6 May 2021

Mechano-immunological response to SARS-CoV-2

In a recent study, researchers demonstrated a human organ-on-a-chip (Organ Chip) microfluidic model of the lung alveolus (Alveolus Chip) - that recapitulates the human alveolar-capillary interface with an air-liquid interface (ALI) and vascular fluid flow to understand the local triggers in the lung in vitro.

5 May 2021

Stem cell therapy for COVID-19 and ARDS

In a review paper recently uploaded to the journal Biomedicine & Pharmacotherapy by Mahendiratta et al. (May 2021) the applicability of stem cells in treating severe SARS-CoV-2 infection is investigated, with regard to ARDS therapy.

5 May 2021

Researchers identify mechanism of platelet hyperactivation in COVID-19 patients

A recent study conducted at the University of Pennsylvania and the Children’s Hospital of Philadelphia, USA, has revealed the mechanism of platelet hyperactivation in critically ill coronavirus disease 2019 (COVID-19) patients.

4 May 2021

Evidence that elevated blood glucose is a significant risk factor for severe COVID-19

The literature analysis pointed to elevated blood glucose levels as a leading facilitator in the progression of COVID-19. Evidence linking elevated glucose to various steps in the life cycle of the virus and presentation of COVID-19 symptoms were also found.

3 May 2021

New treatment reduces the severity of ARDS in influenza-infected mice

A new treatment is among the first known to reduce the severity of acute respiratory distress syndrome caused by the flu in animals, according to a new study.

27 Apr 2021

Celastrol shows potential anti-SARS-CoV-2 activity

A new study published on the bioRxiv* preprint server focuses on the in-silico predictions to repurpose existing drug compounds, that may have the ability to reverse the SARS-CoV-2 gene expression induced in host cells.

23 Apr 2021